human protein C

This medicine is authorised for use in the European Union.


Ceprotin is a medicine used in patients with severe congenital protein C deficiency, a condition that increases the risk of blood clots. It is used to treat and prevent:

  • purpura fulminans (extensive clotting of blood within the blood vessels, which causes the death of the tissues just beneath the skin, often leading to organ failure and amputations);
  • coumarin-induced skin necrosis (a complication of medicines used to prevent blood clotting such as warfarin, which causes skin death);
  • venous thromboembolism (problems due to the formation of blood clots in the veins).

Ceprotin contains the active substance human protein C.

This EPAR was last updated on 02/02/2023

Authorisation details

Product details
Agency product number
Active substance
human protein C
International non-proprietary name (INN) or common name
human protein C
Therapeutic area (MeSH)
  • Purpura Fulminans
  • Protein C Deficiency
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Takeda Manufacturing Austria AG
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Industriestrasse 67
1221 Vienna

Product information

16/12/2022 Ceprotin - EMEA/H/C/000334 - II/0127

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

CEPROTIN is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.

Assessment history

Related content

How useful was this page?

Add your rating